A Ki-67 percentage can look like a simple number, yet it only makes sense beside the rest of your pathology report. In breast cancer Ki-67 testing, the Ki-67 proliferation index estimates how many tumour cells were actively dividing when the tissue sample was taken.
For patients and families in Malaysia, the useful question isn’t whether a result is “good” or “bad.” It’s how the number fits with tumour type, grade, stage, lymph-node findings, estrogen receptor, progesterone receptor, HER2 status, scans, medical history, and the oncologist’s assessment. Start with the percentage’s meaning, then discuss its place in your individual report and proposed breast cancer treatment.
Quick Answer
Ki-67 is a marker of tumor proliferation. A result of 20% means about 20 out of every 100 counted invasive cancer cells showed Ki-67 staining.
This percentage doesn’t describe the whole breast or recurrence risk. However, Ki-67 is not a cancer stage, and it should not decide chemotherapy or hormone therapy on its own.
5 Key Takeaways
- Ki-67 measures the proportion of breast cancer cells that appear to be dividing in a tissue sample.
- Results at 5% or below are generally considered clearly low, while results of 30% or above are generally clearly high.
- A 20% result is used in some clinical settings, but it is not a universal cut-off for every breast cancer.
- Your oncologist interprets Ki-67 with ER, PR, HER2, tumour grade, lymph-node findings, scans, and cancer staging.
- A pathology review or oncology second opinion may help when the result is borderline or strongly affects a major treatment decision.
What a breast cancer Ki-67 result measures
Ki-67 is a protein found in cell nuclei during active phases of cell division. It is associated with the MKI67 gene, but routine testing measures protein staining rather than directly sequencing the gene.
Pathologists estimate the Ki-67 proliferation index through immunohistochemistry analysis. The sample may come from a breast biopsy or surgical specimen. A MIB1 antibody commonly detects the staining. Some laboratories use digital image analysis to assist counting, under pathologist oversight.
The test does not diagnose breast cancer. Instead, it adds information after tissue sampling or surgery has confirmed the cancer type.
What a result such as Ki-67 20% means
A pathology report may state “Ki-67: 20%” or “Ki-67 index: 20%.” This describes the proportion of counted tumour cells that stained positive, or approximately 20 of every 100 cells counted.
It does not mean that 20% of the breast contains cancer. It also does not state that the cancer has a 20% chance of spreading, returning, or responding to treatment.
Why Ki-67 is not the same as cancer stage
Cancer stages describe the size of the tumour, nearby lymph-node involvement, and distant spread. Ki-67 describes the biological activity of cells in the sample.
A small early-stage tumour can have a high Ki-67 result. Conversely, a larger tumour may have a lower one. Your cancer specialist combines both kinds of information when discussing diagnosis and treatment.
How to interpret low, intermediate and high percentages
Ki-67 percentages are most helpful at the clearer ends of the range. The International Ki67 in Breast Cancer Working Group identifies results of 5% or below as clearly low, and 30% or above as clearly high, in particular early breast cancer and prognostic settings.
The middle range needs more care because scoring differences can have a greater effect.
Results at 5% or below, and 30% or above
A Ki-67 result of 5% or lower usually supports low proliferation. A result of 30% or higher supports high proliferation in the relevant clinical settings.
High proliferation can be associated with more active tumour biology. Still, it’s one finding, not a verdict. The ASCO biomarker guideline states that Ki-67 should be considered with other clinical and pathology features rather than used as a stand-alone treatment selector.
An oncologist should interpret the result with tumour grade, hormone receptors, HER2 status, stage, and other pathology findings.
Why 20% appears in reports and discussions
Some laboratories and clinical frameworks use 20% as one of several cut-off points when discussing Luminal A-like and Luminal B-like breast cancers. These frameworks may assess proliferation alongside hormone-receptor findings when describing Luminal A and Luminal B disease.
However, this does not make 20% a universal dividing line. Results such as 18%, 20%, or 22% can fall within a clinically uncertain middle range. Different laboratories may use validated local methods and reporting practices, so results near these cut-off points need context.
A borderline Ki-67 result should prompt a discussion about the full pathology picture, not a treatment decision based on one percentage alone.
Ki-67, Luminal A and Luminal B breast cancer
For hormone receptor-positive, HER2-negative breast cancer, Ki-67 can help describe whether the tumour has features closer to Luminal A-like or Luminal B-like disease. Luminal A-like cancers often have lower proliferation and stronger estrogen receptor expression, while Luminal B-like cancers may show higher proliferation, higher grade, or other higher-risk features. These labels describe tumour biology, not stand-alone treatment decisions.
Hormone receptors and HER2 still matter
Estrogen receptor, progesterone receptor, and HER2 status often have more direct roles in breast cancer treatment discussions. Hormone receptor-positive disease may be treated with endocrine therapy, while HER2-positive disease may involve targeted therapy. Ki-67 interpretation and treatment discussions also differ in triple negative breast cancer.
Ki-67 cannot replace these biomarkers. It adds one piece of tumour biology to the report. A Luminal A-like description doesn’t determine whether chemotherapy or endocrine therapy is needed.
Grade and lymph nodes add further context
Tumour grade reflects how abnormal cancer cells look under a microscope. Grade, lymph-node findings, and stage can carry more direct treatment implications than a Ki-67 percentage alone. These findings can affect discussions about cancer surgery, radiotherapy, chemotherapy, and hormone therapy.
Your oncology consultation should bring these findings together rather than treating Ki-67 as an isolated answer.
Why Ki-67 scores can differ
Ki-67 testing is more sensitive to laboratory processes than many patients realise. Tissue handling after surgery or biopsy, fixation time, staining method, and the area selected for counting can all affect the result.
The stained Ki-67 protein is related to the MKI67 gene, but routine Ki-67 testing isn’t a direct gene-expression test. A core needle biopsy and the later surgical specimen can also produce different scores because of tissue heterogeneity within a tumour.
Manual scoring has limits
A pathologist may count stained cells in selected parts of the tumour. When staining is uneven, two trained observers may choose different fields or reach different percentages. This is one form of interobserver variability.
Such interobserver variability doesn’t mean your report is unreliable. It explains why a result near a cut-off deserves careful interpretation.
Digital pathology may improve consistency
Validated digital image analysis can assist pathologists by applying a defined method to tumour areas and supporting cell counts. It may improve reproducibility, particularly when laboratories follow shared quality-control processes.
Digital image analysis may improve consistency, but it doesn’t remove uncertainty. A 2025 study of global Ki-67 scoring methods supports assessing the tumour more broadly rather than focusing only on small high-staining areas.
Even digital image analysis requires validated protocols, local quality controls, and pathologist review. A differing score doesn’t prove that either laboratory was incorrect.
How Ki-67 can affect cancer treatment discussions
Ki-67 is mainly a prognostic biomarker. It can help your team estimate whether the tumour appears more or less proliferative. It doesn’t automatically identify which cancer treatment option you should receive.
Decisions also depend on tumour type and location, stage, grade, lymph nodes, scans, margins, biomarker and genomic testing, age, menopause status, co-existing conditions, overall health, treatment access in Malaysia, local guidance, hospital capabilities, and your oncologist’s assessment.
Chemotherapy and endocrine therapy
For selected postmenopausal patients with stage I or II estrogen receptor-positive, HER2-negative breast cancer, Ki-67 may contribute to chemotherapy decisions when a genomic test isn’t available. It should still be considered alongside other pathology features.
Ki-67 may also be measured before chemotherapy or other neoadjuvant therapy. Research continues on whether changes after short pre-operative endocrine therapy can indicate hormone sensitivity. A Ki-67 change doesn’t prove a pathological complete response. It also isn’t a substitute for assessing a pathological complete response. Current guidance differs on how much that change should influence later treatment choices, particularly because the evidence isn’t the same in triple negative breast cancer.
CDK4/6 inhibitors and high-risk early disease
In selected node-positive, high-risk early breast cancers, a Ki-67 result of at least 20% has been used within eligibility discussions for abemaciclib alongside endocrine therapy. The relevant class is CDK4/6 inhibitors. These CDK inhibitors may be considered only after reviewing the full clinical picture.
This doesn’t mean everyone with Ki-67 of 20% needs a CDK inhibitor. Eligibility for CDK inhibitors depends on the full approved criteria, not Ki-67 alone. Access, side effects, co-existing conditions, pathology findings, local treatment guidance, and an oncologist’s assessment all matter.
Ki-67 compared with Oncotype DX and MammaPrint
Ki-67 is an IHC measurement of cell division. Oncotype DX and MammaPrint are multigene assays that examine gene activity in tumour tissue. They measure different aspects of tumour biology and can answer related but different questions.
Oncotype DX produces a Recurrence Score from 0 to 100 for selected early-stage, estrogen receptor-positive, HER2-negative invasive breast cancers. It may be considered when the likely benefit of chemotherapy remains uncertain.
These tests are not interchangeable
A high Ki-67 result doesn’t always match a high Oncotype DX score. Research has found only a modest association and meaningful disagreement between the two tests, as described in this Ki-67 and Oncotype DX comparison.
MammaPrint also provides genomic risk information, but these tests don’t replace tumour type, grade, stage, lymph-node findings, hormone receptors, HER2 status, scans, or the oncologist’s assessment. Results from triple negative breast cancer can’t simply be applied without disease-specific evidence and specialist interpretation. Ask whether a genomic test would answer a question that Ki-67 cannot answer in your case.
When to request a report review or second opinion
You may want another specialist opinion when your Ki-67 result is near a threshold, differs between samples, or affects a chemotherapy decision. A second opinion can confirm the original plan, clarify the report, recommend further assessment, or identify another medically appropriate approach.
It does not mean your first doctor is wrong, and it does not mean another treatment will always be available.
Prepare complete medical information
Bring your biopsy report, surgical pathology report, ER, PR and HER2 results, imaging reports, treatment notes, medication list, and any genomic assay result. If available, request the original scan images and pathology slides through your treating hospital.
For help organising information for review or an overseas specialist enquiry, Explore Medical Report Review Support. This coordination support does not replace a pathologist’s or oncologist’s medical interpretation.
Ask focused questions at your oncology consultation
Consider asking:
- Was my Ki-67 measured on a biopsy or surgical specimen, and was the sample adequate?
- How do my Ki-67, grade, ER, PR, HER2, stage, and lymph nodes affect the proposed plan?
- Could interobserver variability or different tumour areas explain the difference between my biopsy and surgical result?
- Was digital image analysis used, and is the laboratory’s method validated?
- Would Oncotype DX or another genomic test add useful information?
- Does my result change the role of chemotherapy, radiotherapy, or hormone therapy?
- If relevant to my pathology and proposed plan, could CDK inhibitors be considered?
- Is a pathology report review reasonable before I make this decision?
If you need a cancer second opinion, Explore Cancer Second Opinion Support for medical-travel and specialist-review coordination. Qualified doctors remain responsible for diagnosis and treatment recommendations.
Frequently asked questions about Ki-67
Is Ki-67 of 20% high?
A result of 20% is often considered intermediate or moderately increased. Some frameworks use 20% as a high-proliferation threshold, but it is not universal. Your report needs interpretation alongside other breast cancer biomarkers.
Does a high Ki-67 mean I need chemotherapy?
No. A high result may strengthen the discussion about chemotherapy in some cases, but it cannot decide treatment alone. The same caution applies to CDK inhibitors, which require full eligibility criteria. Your oncologist will also consider the stage of cancer, lymph nodes, grade, HER2, hormone receptors, genomic testing, and your health.
Can Ki-67 change after treatment starts?
It can change, particularly with pre-operative endocrine therapy. However, a change does not automatically dictate the next treatment. Your specialist will decide whether repeat testing has a useful role.
Should I consider treatment overseas because of my Ki-67 result?
A Ki-67 result by itself is not a reason to seek overseas cancer treatment. Different cancer hospitals may have different specialists, technologies, waiting times, costs, and treatment availability. Explore Overseas Hospital Options if you want coordination support for hospital enquiries, while keeping treatment decisions with qualified oncology teams.
A percentage needs a full clinical picture
Breast cancer Ki-67 is most useful when considered alongside the rest of your pathology and treatment discussion. As a prognostic biomarker, it provides context rather than a stand-alone forecast. Clear low and high results can add prognostic context, while intermediate results require more caution.
Interpretation requires the tumour type, grade, stage, estrogen receptor, progesterone receptor, HER2 status, scans, medical history, and oncologist’s assessment. Ki-67 can’t calculate an individual recurrence rate or predict an individual survival outcome. Before agreeing to a major treatment change, ask how the percentage affects your own cancer treatment plan. If the answer remains unclear, a report review or another qualified specialist perspective may help you make an informed decision.
Medical disclaimer: This article provides general educational information only and may not apply to every patient. It is not medical advice, a diagnosis, or a treatment recommendation. Cancer treatment decisions depend on individual clinical circumstances, and you should consult your own doctor, oncologist, or qualified healthcare professional before making medical decisions.
